The Hindu Business Line : MSD launches diabetics drug

MSD Pharmaceuticals Pvt Ltd, a wholly owned subsidiary of Merck & Co Inc, launched `Januvia', an oral drug for Type II diabetes here on Wednesday. The drug (Sitagliptin) is first in the class of drugs known as Dipeptidyl Peptidase-4 (DPP-4) inhibitors which enhance the body's own ability to lower blood sugar when it is elevated, Dr Naveen Rao, Managing Director, MSD Pharmaceuticals, told newspersons here on Wednesday. The drug is now being sold in 60 cities across the country at a price of Rs 42.80 a tablet. MSD Pharmaceuticals would be ramping up its operations in India by doubling its number of employees to 800 from the current 400 by the year-end, he added. - Our Bureau

More Stories on : New Products & Services | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Mount Everest Mineral Water expanding retail presence

Super-bikes maker Ducati enters Indian market

SABMiller looks to introduce premium beer brands in India

Decision on FDI in retail unlikely in UPA regime

Arvind Brands inks pact with Hartmarx Corpn

Akshaya Tritiya sales rush missing due to high gold prices

Funds for Gujarati edition of CERC bi-monthly

Mirinda unveils new campaign

Injunction in favour of Britannia

Foot play

Television audience metering needs no Govt intervention, says industry

Walt Disney TV appoints new head

MSD launches diabetics drug